The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 02, 2018

Filed:

Jul. 15, 2016
Applicant:

Ajou University Industry-academic Cooperation Foundation, Suwon-si, Gyeonggi-do, KR;

Inventors:

Sang Myun Park, Suwon-si, KR;

Yu Ree Choi, Suwon-si, KR;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 31/47 (2006.01); C12N 15/113 (2010.01); G01N 33/68 (2006.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A61K 31/47 (2013.01); C12N 15/1137 (2013.01); C12Y 301/03048 (2013.01); G01N 33/5058 (2013.01); G01N 33/6854 (2013.01); G01N 33/6896 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2310/16 (2013.01); C12N 2310/531 (2013.01); G01N 2333/70535 (2013.01); G01N 2500/10 (2013.01); G01N 2800/2814 (2013.01); G01N 2800/2835 (2013.01);
Abstract

This invention provides a method of treating a neurodegenerative disease selected from the group consisting of Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, comprising administering a pharmaceutically effective amount of an agent capable of suppressing expression or activity of SHP-1/-2 (Src homology region 2 domain-containing phosphatase-1/-2) or FcγRIIB (IgG Fc receptor II-B) to a subject having the neurodegenerative disease, wherein the agent capable of suppressing expression of SHP-1/-2 or FcγRIIB is selected from the group consisting of miRNA, siRNA, shRNA, antisense oligonucleotide, and a combination thereof capable of specifically binding to mRNA of SHP-1/-2 or FcγRIIB, and the agent capable of suppressing activity of SHP-1/-2 or FcγRIIB is selected from the group consisting of an antibody, an aptamer, an antagonist, and a combination thereof capable of specifically binding to a protein of SHP-1/-2 or FcγRIIB.


Find Patent Forward Citations

Loading…